Galux
Seoul company whose GaluxDesign platform combines AI with physics-based modelling to design high-affinity antibodies and other protein therapeutics from scratch, extending to hard targets such as GPCRs and ion channels, with an internal wet lab returning experimental data to the models.
Headquarters
Seoul, South Korea
Year Founded
2020
Founders
Chaok Seok (CEO), Taeyong Park (co-CEO)
Country
South Korea
Financial Information
Funding Stage
Series B
Recent Funding
$47M
Funding By
InterVest, DAYLI Partners, PATHWAY Investment, Korea Development Bank, Korea Investment & Securities, Mirae Asset Securities
Core Technology
GaluxDesign: AI integrated with physics-based protein modelling
Product Type
AI Platform
Pipeline Stage (Very Important)
Regulatory Status
- IND Filed: No
- FDA/EMA Status: N/A
- Clinical Trial Registration: N/A
- Patents / IP Status: Not disclosed
Partnerships
Pharma Collaborations
Celltrion, LG Chem, Boehringer Ingelheim (co-development partnerships)
Academic / Hospital Tie-ups
Seoul National University (research roots)
CRO/CDMO Partnerships
In-house wet lab
Market & Differentiation
AI-designed antibody structures validated against cryo-EM data, targeting GPCRs and ion channels